Logo image of PHGE

BIOMX INC (PHGE) Stock Price, Quote, News and Overview

NYSEARCA:PHGE - American Stock Exchange - US09090D3017 - Common Stock - Currency: USD

0.7096  -0.03 (-3.46%)

PHGE Quote, Performance and Key Statistics

BIOMX INC

NYSEARCA:PHGE (2/4/2025, 8:04:01 PM)

0.7096

-0.03 (-3.46%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High8.55
52 Week Low0.48
Market Cap12.90M
Shares18.18M
Float13.62M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO12-18 2018-12-18


PHGE short term performance overview.The bars show the price performance of PHGE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

PHGE long term performance overview.The bars show the price performance of PHGE in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PHGE is 0.7096 USD. In the past month the price decreased by -8.38%. In the past year, price decreased by -68.46%.

BIOMX INC / PHGE Daily stock chart

PHGE Latest News, Press Releases and Analysis

News Image
2 months ago - BiomX

BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

NESS ZIONA, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing...

News Image
3 months ago - BiomX

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 ...

News Image
3 months ago - BiomX

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing...

News Image
4 months ago - BiomX

BiomX Announces a Mandatory Unit Separation

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing...

News Image
5 months ago - BiomX

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing...

PHGE Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.77 335.67B
AMGN AMGEN INC 15.04 155.36B
VRTX VERTEX PHARMACEUTICALS INC 945.65 124.20B
GILD GILEAD SCIENCES INC 22.12 122.12B
REGN REGENERON PHARMACEUTICALS 15.34 76.60B
ARGX ARGENX SE - ADR N/A 38.95B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.95B
BNTX BIONTECH SE-ADR N/A 28.08B
ONC BEIGENE LTD-ADR N/A 23.76B
NTRA NATERA INC N/A 23.00B
BIIB BIOGEN INC 8.73 20.76B
UTHR UNITED THERAPEUTICS CORP 15.52 15.78B

About PHGE

Company Profile

PHGE logo image Biomx Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Gaithersburg, Maryland and currently employs 58 full-time employees. The company went IPO on 2018-12-18. BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Company Info

BIOMX INC

708 Quince Orchard Rd, Suite 205

Gaithersburg MARYLAND 7414002 US

CEO: Jonathan Solomon

Employees: 65

Company Website: https://www.biomx.com/

Investor Relations: http://ir.biomx.com/

Phone: 18449720500

PHGE FAQ

What is the stock price of PHGE?

The current stock price of PHGE is 0.7096 USD.


What is the symbol for BIOMX INC stock?

The exchange symbol of BIOMX INC is PHGE and it is listed on the American Stock Exchange exchange.


On which exchange is PHGE stock listed?

PHGE stock is listed on the American Stock Exchange exchange.


Is PHGE a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PHGE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PHGE.


Does PHGE stock pay dividends?

PHGE does not pay a dividend.


What is the Price/Earnings (PE) ratio of PHGE?

PHGE does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.3).


What is the Short Interest ratio of PHGE stock?

The outstanding short interest for PHGE is 0.22% of its float.


PHGE Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to PHGE. When comparing the yearly performance of all stocks, PHGE is a bad performer in the overall market: 93.19% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PHGE Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PHGE. While PHGE seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PHGE Financial Highlights

Over the last trailing twelve months PHGE reported a non-GAAP Earnings per Share(EPS) of -5.3. The EPS decreased by 43.62% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -14.51%
ROE -22.97%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%552.59%
Sales Q2Q%N/A
EPS 1Y (TTM)43.62%
Revenue 1Y (TTM)N/A

PHGE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to PHGE. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners5.29%
Ins Owners0.62%
Short Float %0.22%
Short Ratio0.37
Analysts
Analysts82.5
Price Target7.14 (906.2%)
EPS Next Y50.83%
Revenue Next YearN/A